Global Cachexia Pipeline Report 2021: Comprehensive Insights About 22+ Companies and Respective Pipeline Drugs
Dublin, June 30, 2021 (GLOBE NEWSWIRE) -- The "Cachexia - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
This "Cachexia - Pipeline Insight, 2021" report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Cachexia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Cachexia R&D. The therapies under development are focused on novel approaches to treat/improve Cachexia.
Cachexia Emerging Drugs Chapters
This segment of the Cachexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cachexia Emerging Drugs
GCWB 204: Green Cross Wellbeing
GCWB 204 (BST 204), a purified ginseng extract with reinforced ginsenosides Rh2 and Rg3. Green Cross Wellbeing is developing the drug as oral capsule in Phase II clinical studies for the treatment of cancer cachexia.
Ponsegromab: Pfizer
Ponsegromab (formerly PF-06946860) is subcutaneous, monoclonal antibody directed against the human growth differentiation factor 15 (GDF15; MIC-1). The drug is in Phase I clinical developmental studies for the treatment of Cachexia.
Cachexia: Therapeutic Assessment
This segment of the report provides insights about the different Cachexia drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Cachexia
There are approx. 22+ key companies which are developing the therapies for Cachexia. The companies which have their Cachexia drug candidates in the most advanced stage, i.e. Phase II include, Green Cross Wellbeing.
Phases
This report covers around 22+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Cachexia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravitreal
Subretinal
Topical
Molecule Type
Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Cachexia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cachexia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cachexia drugs.
Cachexia Report Insights
Cachexia Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs
Cachexia Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Cachexia drugs?
How many Cachexia drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cachexia?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cachexia therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Cachexia and their status?
What are the key designations that have been granted to the emerging drugs?
Key Players
Incyte Corporation
Green Cross Wellbeing
AEterna Zentaris
AVEO Oncology
AstraZeneca
Endevica Bio
Actimed Therapeutics
Creative Medical Technology Holdings
Ildong Pharmaceutical
Immuneering
Key Products
Ruxolitinib
GCWB 204
Macimorelin
AV 380
ART 2713
TCMCB-07
ACM-002
Research programme: amniotic stem cell therapies
ID 11917
Research programme: cancer therapeutics
Key Topics Covered:
Introduction
Executive Summary
Cachexia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Cachexia - Analytical Perspective
In-depth Commercial Assessment
Cachexia companies' collaborations, Licensing, Acquisition -Deal Value Trends
Cachexia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
GCWB 204: Green Cross Wellbeing
Product Description
Research and Development
Product Development Activities
Early Stage Products (Phase I)
Comparative Analysis
Ponsegromab: Pfizer
Product Description
Research and Development
Product Development Activities
Preclinical/Discovery Stage Products
Comparative Analysis
TCMCB-07: Endevica Bio
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
Cachexia Key Companies
Cachexia Key Products
Cachexia- Unmet Needs
Cachexia- Market Drivers and Barriers
Cachexia- Future Perspectives and Conclusion
Cachexia Analyst Views
Cachexia Key Companies
Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/hcx7w5
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900